Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 3
1(25.0%)
4Total
N/A(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04793750Not ApplicableCompleted

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)

Role: collaborator

NCT06369220Not ApplicableCompleted

A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections

Role: collaborator

NCT02525939Phase 3Completed

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Role: collaborator

NCT01317498Not ApplicableCompleted

The VMVN Study: Virological Monitoring in Viet Nam

Role: collaborator

NCT02067286Completed

Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer

Role: collaborator

NCT02068469Completed

In Vitro Diagnostic Device for the Detection of Strep A

Role: collaborator

All 6 trials loaded